News Medical on MSN1d
Certain genetic alterations may contribute to primary resistance of certain cancers to KRAS G12C inhibitorsThe KRAS G12C mutation is found in approximately 3% of all colorectal cancer cases and 1% to 2% of pancreatic adenocarcinoma ...
In patients with pancreatic ductal adenocarcinoma, KRAS G12D and G12V mutations hare associated with worse patient outcomes, ...
The BIRAC funding will enable comprehensive toxicology assessments, a necessary step in preparing for IND submission with ...
Krazati plus Erbitux is well tolerated in KRAS G12C-mutant metastatic colorectal cancer, with manageable side effects and ...
For a while, special purpose acquisition companies were biotech’s hot ticket to the public markets. | For a while, special ...
LTIMindtree has implemented a new appraisal system for middle and senior-level managers that ties salary hikes to competency ...
PESG Research releases a new market update on Silexion Therapeutics (NASDAQ: SLXN). Silexion recently announced the completion of its initial study evaluating SIL-204 in orthotopic pancreatic cancer ...
6don MSN
Multidrug resistance in cancer can be overcome by combining a drug that blocks a key enzyme with another anticancer drug, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback